EIDX Soars on Billion-Dollar Merger

EIDX is hitting a new record high

Assistant Editor
Oct 5, 2020 at 9:29 AM
facebook twitter linkedin


Eidos Therapeutics Inc (NASDAQ:EIDX) is surging today, up 34.2% at $69.67 at last check, after announcing a merger with BridgeBio Pharma Inc (BBIO). More specifically, BridgeBio is set to buy Eidos Therapeutics in a cash-and-stock deal of about $2.8 billion. Shareholders of Eidos will have the option to either 1.85 shares of BBIO or to cash out at $73.26 per share up to $175 million -- a 41.1% premium to Friday's close. 

Ahead of the news, EIDX was down 9.5% year-to-date, and hanging out at familiar pressure at the $53-$54 region. Now, the equity is surpassing its record Dec. 16 high of $66.55.

Analysts were split on Eidos stock coming into today, with three in coverage at a "strong buy," three at a "hold," and one sporting a "strong sell." Meanwhile, the 12-month consensus price target of $59.38 is a 14.4% premium to Friday's close. 

Meanwhile, the 1.89 million shares sold short account for 15.1% of the stock's available float. In other words, it would take over 27 days to cover these bearish bets at EIDX's average pace of trading. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners